<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545543</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-QIV-13-02</org_study_id>
    <nct_id>NCT02545543</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age</brief_title>
  <official_title>A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-Licensed 2015-2016 Quadrivalent Inactivated Comparator Influenza Vaccine (Comparator QIV) in a Pediatric Population 5 Through 17 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the immune (antibody) response and safety of a Seqirus split
      virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US
      licensed 2015/2016 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric
      population 5 through 17 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Geometric Mean Titer (GMT) Ratio of Each Virus Strain.</measure>
    <time_frame>28 days after last vaccination.</time_frame>
    <description>Noninferiority of Seqirus QIV compared to comparator QIV was assessed by the eight co-primary endpoints of hemagglutination inhibition (HI) antibody geometric mean titer (GMT) and seroconversion rate (SCR) for each viral strain included in the vaccines. The GMT ratio is defined as the geometric mean of the postvaccination HI titer for the US-licensed comparator QIV over the geometric mean of the postvaccination HI titer for Seqirus QIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Difference in Seroconversion Rate (SCR) for Each Virus Strain.</measure>
    <time_frame>28 days after last vaccination.</time_frame>
    <description>Noninferiority of Seqirus QIV compared to Comparator QIV was assessed by the eight co-primary endpoints of HI geometric mean titer (GMT) and seroconversion rate (SCR) for each viral strain. The rate of SCR is defined as the percentage of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40, or a prevaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination HI titer. For the SCR comparison, the difference between the SCR for each virus strain will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: The Frequency and Severity of Solicited Local Adverse Reactions.</measure>
    <time_frame>7 days after each vaccination.</time_frame>
    <description>Frequency and severity of solicited local adverse reactions (AEs) for 7 days (ie, day of vaccination and 6 subsequent days) after each vaccination dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: The Frequency and Severity of Solicited Systemic Adverse Events (AEs).</measure>
    <time_frame>7 days after each vaccination.</time_frame>
    <description>Frequency and severity of solicited systemic adverse events (AEs) for 7 days (ie, day of vaccination and 6 subsequent days) after each vaccination dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: The Frequency of Cellulitis-like Reaction.</measure>
    <time_frame>28 days after each vaccination.</time_frame>
    <description>Frequency of cellulitis-like reaction for at least 28 days after each vaccination dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: The Frequency and Severity of Unsolicited Adverse Events (AEs).</measure>
    <time_frame>28 days after each vaccination.</time_frame>
    <description>Frequency and severity of unsolicited AEs for at least 28 days (ie, day of vaccination and 27 subsequent days) after each vaccination dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: The Frequency of Serious Adverse Events (SAEs).</measure>
    <time_frame>180 days after the last vaccination dose.</time_frame>
    <description>Frequency of serious adverse events (SAEs) for 180 days after the last vaccination dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMTs - Geometric Mean of HI Titers Prevaccination (Day 1) and Postvaccination (Study Exit Visit)</measure>
    <time_frame>28 days after last vaccination.</time_frame>
    <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- Geometric mean of HI titers prevaccination &amp; postvaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Seroconversion Rate (SCR)</measure>
    <time_frame>28 days after last vaccination.</time_frame>
    <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- SCRs: % of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Seroprotection Rate</measure>
    <time_frame>28 days after last vaccination.</time_frame>
    <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- The % of subjects with a titer ≥40 (seroprotection rates) at Day 1 and at Exit Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Geometric Mean Fold Increase (GMFI)</measure>
    <time_frame>28 days after last vaccination.</time_frame>
    <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- Geometric mean fold increase (GMFI): geometric mean fold titer rise from Day 1 to Exit Visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2278</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Seqirus Quadrivalent Inactivated Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seqirus QIV</intervention_name>
    <description>Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
    <arm_group_label>Seqirus Quadrivalent Inactivated Influenza Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator QIV</intervention_name>
    <description>The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
    <arm_group_label>Comparator Quadrivalent Influenza Vaccine</arm_group_label>
    <other_name>Fluarix Quadrivalent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 5 through 17 years of age on the day of first study vaccination.

          -  Parent or legally acceptable representative able to provide written informed consent
             and be willing and able to adhere to all protocol requirements including blood draws.
             Participant assent will also be obtained if required.

          -  If applicable, females of childbearing potential (ie, ovulating, not surgically
             sterile) must be abstinent or be willing to use a medically accepted contraceptive
             regimen until at least 28 days after the last Study Vaccine. Females of childbearing
             potential must return a negative urine pregnancy test result, prior to any vaccination
             dose with the Study Vaccine.

        Exclusion Criteria:

          -  History of allergic reactions to egg proteins or any components of the Study Vaccines.

          -  History of serious adverse reactions to any influenza vaccines.

          -  History of Guillain-Barré syndrome or other demyelinating disease.

          -  History of licensed or investigational influenza vaccination in the last 6 months.

          -  Clinical signs of active infection and/or an oral temperature of ≥ 100°F (37.8°C) on
             the day of planned Study Vaccine administration or within 48 hours preceding
             vaccination.

          -  Current or recent, acute or chronic medical conditions that in the opinion of the
             Investigator are clinically significant and/or unstable (such as illness
             exacerbations) within the preceding 30 days.

          -  History of any seizures, with the exception of a single febrile seizure.

          -  Self-reported or known seropositivity suggestive of acute or chronic viral infection
             for human immunodeficiency virus, hepatitis B or hepatitis C.

          -  Known or suspected congenital or acquired immunosuppressive conditions.

          -  Current or recent immunosuppressive or immunomodulatory therapy, as follows:

               -  Chronic or long-term systemic corticosteroids: ≥ 0.125 mg/kg/day of oral
                  prednisolone or equivalent daily;

               -  Sporadic systemic corticosteroids: ≥ 0.5 mg/kg/day of oral prednisolone or
                  equivalent for two or more short courses of &gt; 3 days in the 3 months preceding
                  vaccination;

               -  Antineoplastic chemotherapy or radiation therapy within the 6 months preceding
                  vaccination.

        Note: Use of topical, inhalant or localised tissue injections of corticosteroids prior to
        administration of the Study Vaccine or throughout the study are acceptable.

          -  Administration of immunoglobulin and/or any blood products within the 3 months
             preceding vaccination, or planned administration during the study.

          -  Participation in a clinical trial or use of an investigational compound within 28 days
             prior to the first dose of Study Vaccine, or within 28 days after receiving the final
             indicated dose of Study Vaccine, or plans to enter a study during this period.

          -  Vaccination with a licensed vaccine 28 days (for live or inactivated vaccines) prior
             to receiving the first dose of Study Vaccine, or plans to receive any licensed vaccine
             prior to the Study Exit Visit.

          -  Pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Physician Seqirus</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 296</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 401</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 397</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 392</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 402</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 398</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 388</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 293</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 289</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 294</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 390</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 396</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 400</name>
      <address>
        <city>Park City</city>
        <state>Kansas</state>
        <zip>67219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 317</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 386</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 393</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 287</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 316</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 382</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 285</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 387</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 385</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 383</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 399</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 384</name>
      <address>
        <city>Grove City</city>
        <state>Ohio</state>
        <zip>43123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 389</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 283</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 282</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 288</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 394</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 395</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 300</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>April 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2017</results_first_posted>
  <disposition_first_submitted>February 10, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 10, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 13, 2017</disposition_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient In: 14-SEP-2015, Last Patient Last Visit: 13-JUN-2016. Number of activated sites that enrolled subjects: 32 (all based in USA).</recruitment_details>
      <pre_assignment_details>Number of subjects screened: 2349. Number of subjects randomized: 2278</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Seqirus Quadrivalent Influenza Vaccine</title>
          <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
        </group>
        <group group_id="P2">
          <title>Comparator Quadrivalent Influenza Vaccine</title>
          <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1709"/>
                <participants group_id="P2" count="569"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1628"/>
                <participants group_id="P2" count="535"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncomplaince</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrolment of subject at &gt;1 study site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set (FAS) was used for analysis of subject characteristics and comprised all subjects who gave informed consent and who were randomized to treatment. Screening failures were not included in the FAS.</population>
      <group_list>
        <group group_id="B1">
          <title>Seqirus Quadrivalent Influenza Vaccine</title>
          <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
        </group>
        <group group_id="B2">
          <title>Comparator Quadrivalent Influenza Vaccine</title>
          <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1709"/>
            <count group_id="B2" value="569"/>
            <count group_id="B3" value="2278"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5" spread="3.49"/>
                    <measurement group_id="B2" value="9.5" spread="3.46"/>
                    <measurement group_id="B3" value="9.5" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>5 through 8 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="875"/>
                    <measurement group_id="B2" value="291"/>
                    <measurement group_id="B3" value="1166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 through 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="834"/>
                    <measurement group_id="B2" value="278"/>
                    <measurement group_id="B3" value="1112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="825"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="1092"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="884"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="1186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="412"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="542"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1293"/>
                    <measurement group_id="B2" value="438"/>
                    <measurement group_id="B3" value="1731"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="359"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="472"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1239"/>
                    <measurement group_id="B2" value="430"/>
                    <measurement group_id="B3" value="1669"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1709"/>
                    <measurement group_id="B2" value="569"/>
                    <measurement group_id="B3" value="2278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Geometric Mean Titer (GMT) Ratio of Each Virus Strain.</title>
        <description>Noninferiority of Seqirus QIV compared to comparator QIV was assessed by the eight co-primary endpoints of hemagglutination inhibition (HI) antibody geometric mean titer (GMT) and seroconversion rate (SCR) for each viral strain included in the vaccines. The GMT ratio is defined as the geometric mean of the postvaccination HI titer for the US-licensed comparator QIV over the geometric mean of the postvaccination HI titer for Seqirus QIV.</description>
        <time_frame>28 days after last vaccination.</time_frame>
        <population>The Per Protocol Population was used for the primary and secondary analysis of immunogenicity data and included subjects in the Evaluable Population minus any subjects with deviations that were thought to potentially affect the immunogenicity results, following medical review prior to unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>GMT Ratios: GMT Comparator QIV Over GMT Seqirus QIV</title>
            <description>GMT Ratios: GMT Comparator Quadrivalent Influenza Vaccine over GMT Seqirus Quadrivalent Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean Titer (GMT) Ratio of Each Virus Strain.</title>
          <description>Noninferiority of Seqirus QIV compared to comparator QIV was assessed by the eight co-primary endpoints of hemagglutination inhibition (HI) antibody geometric mean titer (GMT) and seroconversion rate (SCR) for each viral strain included in the vaccines. The GMT ratio is defined as the geometric mean of the postvaccination HI titer for the US-licensed comparator QIV over the geometric mean of the postvaccination HI titer for Seqirus QIV.</description>
          <population>The Per Protocol Population was used for the primary and secondary analysis of immunogenicity data and included subjects in the Evaluable Population minus any subjects with deviations that were thought to potentially affect the immunogenicity results, following medical review prior to unblinding.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.93" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.96" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.81" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.83" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Difference in Seroconversion Rate (SCR) for Each Virus Strain.</title>
        <description>Noninferiority of Seqirus QIV compared to Comparator QIV was assessed by the eight co-primary endpoints of HI geometric mean titer (GMT) and seroconversion rate (SCR) for each viral strain. The rate of SCR is defined as the percentage of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40, or a prevaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination HI titer. For the SCR comparison, the difference between the SCR for each virus strain will be determined.</description>
        <time_frame>28 days after last vaccination.</time_frame>
        <population>The Per Protocol Population was used for the primary and secondary analysis of immunogenicity data and included subjects in the Evaluable Population minus any subjects with deviations that were thought to potentially affect the immunogenicity results, following medical review prior to unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>SCR Difference = Comparator QIV SCR % Minus Seqirus QIV SCR %</title>
            <description>Seroconversion rate difference = Comparator QIV SCR percentage minus Seqirus QIV SCR percentage</description>
          </group>
        </group_list>
        <measure>
          <title>The Difference in Seroconversion Rate (SCR) for Each Virus Strain.</title>
          <description>Noninferiority of Seqirus QIV compared to Comparator QIV was assessed by the eight co-primary endpoints of HI geometric mean titer (GMT) and seroconversion rate (SCR) for each viral strain. The rate of SCR is defined as the percentage of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40, or a prevaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination HI titer. For the SCR comparison, the difference between the SCR for each virus strain will be determined.</description>
          <population>The Per Protocol Population was used for the primary and secondary analysis of immunogenicity data and included subjects in the Evaluable Population minus any subjects with deviations that were thought to potentially affect the immunogenicity results, following medical review prior to unblinding.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" lower_limit="-8.0" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-4.5" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" lower_limit="-8.3" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-6.9" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: The Frequency and Severity of Solicited Local Adverse Reactions.</title>
        <description>Frequency and severity of solicited local adverse reactions (AEs) for 7 days (ie, day of vaccination and 6 subsequent days) after each vaccination dose</description>
        <time_frame>7 days after each vaccination.</time_frame>
        <population>The Solicited Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and provided any evaluable data on solicited events.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus Quadrivalent Influenza Vaccine</title>
            <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Quadrivalent Influenza Vaccine</title>
            <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: The Frequency and Severity of Solicited Local Adverse Reactions.</title>
          <description>Frequency and severity of solicited local adverse reactions (AEs) for 7 days (ie, day of vaccination and 6 subsequent days) after each vaccination dose</description>
          <population>The Solicited Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and provided any evaluable data on solicited events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1621"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Frequency of Solicited Local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="909"/>
                    <measurement group_id="O2" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe (Grade 3) Solicited Local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: The Frequency and Severity of Solicited Systemic Adverse Events (AEs).</title>
        <description>Frequency and severity of solicited systemic adverse events (AEs) for 7 days (ie, day of vaccination and 6 subsequent days) after each vaccination dose</description>
        <time_frame>7 days after each vaccination.</time_frame>
        <population>The Solicited Safety Population comprised all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and provided any evaluable data on solicited events.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus Quadrivalent Influenza Vaccine</title>
            <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Quadrivalent Influenza Vaccine</title>
            <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: The Frequency and Severity of Solicited Systemic Adverse Events (AEs).</title>
          <description>Frequency and severity of solicited systemic adverse events (AEs) for 7 days (ie, day of vaccination and 6 subsequent days) after each vaccination dose</description>
          <population>The Solicited Safety Population comprised all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and provided any evaluable data on solicited events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1621"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Frequency of Solicited Systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe (Grade 3) Solicited Systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: The Frequency of Cellulitis-like Reaction.</title>
        <description>Frequency of cellulitis-like reaction for at least 28 days after each vaccination dose</description>
        <time_frame>28 days after each vaccination.</time_frame>
        <population>The Solicited Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and provided any evaluable data on solicited events.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus Quadrivalent Influenza Vaccine</title>
            <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Quadrivalent Influenza Vaccine</title>
            <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: The Frequency of Cellulitis-like Reaction.</title>
          <description>Frequency of cellulitis-like reaction for at least 28 days after each vaccination dose</description>
          <population>The Solicited Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and provided any evaluable data on solicited events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1621"/>
                <count group_id="O2" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: The Frequency and Severity of Unsolicited Adverse Events (AEs).</title>
        <description>Frequency and severity of unsolicited AEs for at least 28 days (ie, day of vaccination and 27 subsequent days) after each vaccination dose</description>
        <time_frame>28 days after each vaccination.</time_frame>
        <population>The Overall Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and provided any evaluable follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus Quadrivalent Influenza Vaccine</title>
            <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Quadrivalent Influenza Vaccine</title>
            <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: The Frequency and Severity of Unsolicited Adverse Events (AEs).</title>
          <description>Frequency and severity of unsolicited AEs for at least 28 days (ie, day of vaccination and 27 subsequent days) after each vaccination dose</description>
          <population>The Overall Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and provided any evaluable follow-up safety data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1692"/>
                <count group_id="O2" value="560"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one Unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe (Grade 3) Unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: The Frequency of Serious Adverse Events (SAEs).</title>
        <description>Frequency of serious adverse events (SAEs) for 180 days after the last vaccination dose.</description>
        <time_frame>180 days after the last vaccination dose.</time_frame>
        <population>The Overall Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and provided any evaluable follow-up safety data</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus Quadrivalent Influenza Vaccine</title>
            <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Quadrivalent Influenza Vaccine</title>
            <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: The Frequency of Serious Adverse Events (SAEs).</title>
          <description>Frequency of serious adverse events (SAEs) for 180 days after the last vaccination dose.</description>
          <population>The Overall Safety Population comprises all subjects in the FAS who received at least one dose or partial dose of Study Vaccine and provided any evaluable follow-up safety data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1692"/>
                <count group_id="O2" value="560"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: GMTs - Geometric Mean of HI Titers Prevaccination (Day 1) and Postvaccination (Study Exit Visit)</title>
        <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- Geometric mean of HI titers prevaccination &amp; postvaccination</description>
        <time_frame>28 days after last vaccination.</time_frame>
        <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus Quadrivalent Influenza Vaccine</title>
            <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Quadrivalent Influenza Vaccine</title>
            <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: GMTs - Geometric Mean of HI Titers Prevaccination (Day 1) and Postvaccination (Study Exit Visit)</title>
          <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- Geometric mean of HI titers prevaccination &amp; postvaccination</description>
          <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1605"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.8" lower_limit="106.79" upper_limit="123.33"/>
                    <measurement group_id="O2" value="119.5" lower_limit="105.48" upper_limit="135.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" lower_limit="70.80" upper_limit="79.88"/>
                    <measurement group_id="O2" value="72.1" lower_limit="64.61" upper_limit="80.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="10.12" upper_limit="10.99"/>
                    <measurement group_id="O2" value="10.4" lower_limit="9.69" upper_limit="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="16.10" upper_limit="17.85"/>
                    <measurement group_id="O2" value="16.9" lower_limit="15.42" upper_limit="18.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="858.7" lower_limit="821.46" upper_limit="897.65"/>
                    <measurement group_id="O2" value="875.1" lower_limit="814.14" upper_limit="940.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="803.6" lower_limit="763.01" upper_limit="846.26"/>
                    <measurement group_id="O2" value="825.6" lower_limit="756.12" upper_limit="901.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7" lower_limit="57.52" upper_limit="64.01"/>
                    <measurement group_id="O2" value="54.3" lower_limit="49.65" upper_limit="59.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.9" lower_limit="132.97" upper_limit="149.26"/>
                    <measurement group_id="O2" value="130.3" lower_limit="117.07" upper_limit="145.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Seroconversion Rate (SCR)</title>
        <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- SCRs: % of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination titer</description>
        <time_frame>28 days after last vaccination.</time_frame>
        <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus Quadrivalent Influenza Vaccine</title>
            <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Quadrivalent Influenza Vaccine</title>
            <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Seroconversion Rate (SCR)</title>
          <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- SCRs: % of subjects with either a prevaccination HI titer &lt; 1:10 and a postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination titer</description>
          <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1605"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" lower_limit="64.0" upper_limit="68.7"/>
                    <measurement group_id="O2" value="63.3" lower_limit="59.0" upper_limit="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9" lower_limit="81.0" upper_limit="84.7"/>
                    <measurement group_id="O2" value="83.3" lower_limit="79.9" upper_limit="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" lower_limit="56.0" upper_limit="60.9"/>
                    <measurement group_id="O2" value="55.1" lower_limit="50.8" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" lower_limit="69.8" upper_limit="74.3"/>
                    <measurement group_id="O2" value="70.1" lower_limit="66.0" upper_limit="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Seroprotection Rate</title>
        <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- The % of subjects with a titer ≥40 (seroprotection rates) at Day 1 and at Exit Visit</description>
        <time_frame>28 days after last vaccination.</time_frame>
        <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus Quadrivalent Influenza Vaccine</title>
            <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Quadrivalent Influenza Vaccine</title>
            <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Seroprotection Rate</title>
          <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- The % of subjects with a titer ≥40 (seroprotection rates) at Day 1 and at Exit Visit</description>
          <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1605"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" lower_limit="79.2" upper_limit="83.1"/>
                    <measurement group_id="O2" value="82.0" lower_limit="78.5" upper_limit="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" lower_limit="74.6" upper_limit="78.7"/>
                    <measurement group_id="O2" value="74.2" lower_limit="70.3" upper_limit="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="11.4" upper_limit="14.7"/>
                    <measurement group_id="O2" value="14.2" lower_limit="11.3" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="25.7" upper_limit="30.2"/>
                    <measurement group_id="O2" value="27.8" lower_limit="24.1" upper_limit="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="99.3" upper_limit="99.9"/>
                    <measurement group_id="O2" value="99.6" lower_limit="98.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4" lower_limit="98.9" upper_limit="99.7"/>
                    <measurement group_id="O2" value="99.4" lower_limit="98.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="72.8" upper_limit="77.1"/>
                    <measurement group_id="O2" value="74.2" lower_limit="70.3" upper_limit="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" lower_limit="88.7" upper_limit="91.7"/>
                    <measurement group_id="O2" value="88.6" lower_limit="85.6" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Geometric Mean Fold Increase (GMFI)</title>
        <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- Geometric mean fold increase (GMFI): geometric mean fold titer rise from Day 1 to Exit Visit</description>
        <time_frame>28 days after last vaccination.</time_frame>
        <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
        <group_list>
          <group group_id="O1">
            <title>Seqirus Quadrivalent Influenza Vaccine</title>
            <description>The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Comparator Quadrivalent Influenza Vaccine</title>
            <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Geometric Mean Fold Increase (GMFI)</title>
          <description>The humoral immune response was assessed for Seqirus QIV &amp; comparator QIV. Serum HI titers against the 4 influenza vaccine strains was used to calculate:
- Geometric mean fold increase (GMFI): geometric mean fold titer rise from Day 1 to Exit Visit</description>
          <population>The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.</population>
          <units>Fold Change Titer (GMFI)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1605"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="6.99" upper_limit="8.01"/>
                    <measurement group_id="O2" value="7.3" lower_limit="6.46" upper_limit="8.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="10.09" upper_limit="11.31"/>
                    <measurement group_id="O2" value="11.5" lower_limit="10.32" upper_limit="12.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.44" upper_limit="6.08"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.75" upper_limit="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="7.81" upper_limit="8.84"/>
                    <measurement group_id="O2" value="7.7" lower_limit="6.92" upper_limit="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Local and systemic solicited AEs collected from Day 1 to Day 7. Unsolicited AEs collected for 28 days after each vaccination dose. SAEs collected for 180 days after last vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Seqirus Quadrivalent Influenza Vaccine</title>
          <description>The Seqirus study vaccine is a sterile, thiomersal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
Seqirus QIV: Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
        </group>
        <group group_id="E2">
          <title>Comparator Quadrivalent Influenza Vaccine</title>
          <description>The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
Comparator QIV: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject’s age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gasteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Pancreatic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1019" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="319" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="833" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="254" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="224" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="278" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Malasia and Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="560"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="213" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="251" subjects_at_risk="1692"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="560"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Seqirus agreements and restrictions on publishing may vary with individual investigators; however, Seqirus will not prohibit any investigator from publishing. Seqirus supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Seqirus Clinical Trial Disclosure Lead</name_or_title>
      <organization>Seqirus</organization>
      <phone>1-855-358-8966</phone>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

